Fingolimod real world experience

Fingolimod is a Multiple Sclerosis treatment licensed in Europe since 2011. Its efficacy has been demonstrated in three large phase III trials, used in the regulatory submissions throughout the world. As usual, in these trials the inclusion and exclusion criteria were designed to obtain a homogeneous population, with interchangeable characteristics in the different treatment arms. Although this is the best strategy to achieve a robust answer to the investigation question, it does not guaranty the treatment efficacy in the clinical practice, since in the real world there are concomitant treatments, comorbidities, adherence and persistence challenges. But, to make informed treatment decision for a real life patient, we need to have evidence of the treatment efficacy, what has been called treatment effectiveness. This work aims to review fingolimod effectiveness, using as source of information abstracts, posters and manuscripts. This unorthodox strategy was developed because more than half of the published experience with fingolimod is still on abstracts and posters. Only a small part of the studies reviewed are already published in peer reviewed journals. Fingolimod seems to be, at least, as effective and safe as it was on clinical trials, and with its long term experience no new safety signals were observed. In the Portuguese hospital perspective, early treatment with fingolimod is expected to result in better clinical outcomes associated with a more efficient healthcare resources allocation.

Curricular training report: 7 months as a study coordinator at Blueclinical LTD

The present report describes in detail the activities undertaken under the coordination of clinical and observational studies during the curricular internship at Blueclinical Ltd., inserted in the Master of Pharmaceutical Biomedicine. Blueclinical Ltd.company operates in three different areas: R&D consultancy, management and coordination of trial centers, and a phase I unit. The curricular internship had the duration of seven months during which I was able to perform different tasks relating to coordination of clinical trials in Centro Hospitalar do Baixo Vouga, E.P.E., (CHBV) in Aveiro, Portugal. This academic internship allowed me to develop theoretical and practical skills in the field of clinical trials and observational studies. I also had the opportunity to further the knowledge I gained throughout my academic journey. During this internship, I had the opportunity to interact with different health professionals and develop my knowledge in the field of several therapeutic indications. I also could interact with distinct monitors and sponsors. This experience allowed me to improve time management, communication and problems resolution skills.

Validade e fiabilidade do protocolo de avaliação da qualidade vocal da Universidade de Aveiro

O presente estudo teve como principal objetivo rever a versão original do Protocolo de Avaliação da Qualidade Vocal da Universidade de Aveiro (PAQVUA), criar o respetivo manual, comprovar a validade de conteúdo do PAQVUA assim como a sua fiabilidade inter e intra avaliador. Para rever a versão original do PAQVUA, foi efetuada uma revisão narrativa da literatura, com o objetivo de encontrar informação que revelasse a pertinência, da versão original do protocolo, para assim se efetuarem as alterações necessárias. Para analisar a validade de conteúdo recorreu-se a um painel de peritos, num total de seis, especialistas na área da voz que avaliaram as provas do PAQVUA, folha de registo e manual. Os peritos avaliaram todos os componentes do PAQVUA através do preenchimento de um questionário com o objetivo de se comprovar a relevância, clareza e precisão de cada uma das provas de avaliação e também o conteúdo do seu manual. Para além disso pretendeu-se também comprovar a fiabilidade inter e intra avaliador do PAQVUA. Para isso, o mesmo protocolo foi aplicado duas vezes por duas avaliadoras diferentes e também foi aplicado em dois momentos temporais diferentes por uma só avaliadora. A amostra teve um total de doze participantes. Para analisar estatisticamente os resultados da validade de conteúdo utilizou-se o método gráfico Bland e Altman modificado e o Coeficiente de Correlação Intraclasses (CCI). Para a fiabilidade inter e intra avaliador recorreu-se ao Coeficiente de Correlação de Spearman (ρ) e ao Kappa de Cohen (k). Relativamente aos resultados obtidos com o método Bland e Altman modificado, verificou-se a existência de concordância entre os peritos através da análise dos gráficos, sendo que a maioria dos pontos se encontrou dentro dos limites esperados de concordância. Quanto aos valores do CCI (entre 0.379 e 0.479), estes revelaram uma correlação regular. No que concerne à fiabilidade inter avaliador, os resultados de correlação e concordância apresentaram-se relevantes, com valores de ρ (de Spearman) superiores a 0.700 e valores de k (de Cohen) superiores a 0.600, na maioria dos casos. O mesmo foi constatado para a fiabilidade intra avaliador. Desta forma pode concluir-se que a nova versão do PAQVUA apresenta validade de conteúdo sendo tal comprovado pelo método de Bland-Altman modificado e pelos valores do CCI. Quanto à fiabilidade inter e intra avaliador, pode afirmar-se que o PAQVUA é fiável, porém como a amostra em estudo é pequena, o que a torna pouco representativa, esta conclusão carece de fundamento com base num estudo mais alargado. Apesar da limitação referida, acredita-se que este protocolo é uma mais-valia para o estudo da patologia vocal em ambiente clínico, assim como para a investigação científica nesta área, pois através do PAQVUA podem-se recolher diversas informações relacionadas com a voz, úteis para uma intervenção terapêutica baseada em evidências científicas.

Curricular training report: clinical studies coordination in a clinical research organization vs an investigational site perspective

This report describes my experience of nine months as a trainee of a CRO (Eurotrials, Scientific Consultants), as well as a trainee of a clinical research site (Clinical Academic Center – Braga, Association). This document describes the European framework about clinical research and the Portuguese situation compared to similar countries. The activities developed during this internship are also described. These activities are divided in two phases. The first one occurred in Eurotrials, Scientific Consultants, a CRO specialized in clinical research and scientific advice. The first weeks were dedicated to intensive self-training needed to perform CTA tasks. These tasks included qualification, initiation and monitoring activities related to clinical trials, as well as the development of a quality management system. The second phase took place on 2CA-Braga, a clinical research center located in Hospital of Braga. Clinical studies coordination was the main focus of this second phase of my internship, as well as negotiation of clinical studies agreements. I had also the opportunity to participate in “1as Jornadas de Investigação Clínica e Inovação” (1st Clinical Investigation and Innovation Conference) organized by 2CA-Braga. Globally, this internship was a great opportunity to get knowledge and experience in the implementation and management of clinical trials, in a CRO and clinical research site perspectives. These two perspectives provided an interesting overview about the scientific needs of different players involved in clinical research. To conclude, this internship strengthened the knowledge acquired from my academic background, which make me able to face and overcome new challenges in the clinical research area.

Curricular trainig report as study coordinator in Blueclinical Ltd.

The present report describes in detail the activities and knowledge aquired during my internship as study coordinator in Blueclinical – Investigação e Desenvolvimento em Saúde, Ltd., in order to obtain the master degree in Pharmaceutical Biomedicine. According to the type of services provided, Blueclinical is formed by three business units: Blueclinical Clinical Research Partnership, Blueclinical Phase I and Blueclinical Research and Development. The fact of belonging to such a company gave me the opportunity to be in touch with different areas of pharmaceutical development and to contact with different research teams, which for me was an added advantage to the integration and consolidation of knowledge, as well as in the development and improvement of soft and hard skills. The main activity developed was the coordination of clinical studies, in Unidade Local de Saúde de Matosinhos, E.P.E., which was one of the institutions that established a partnership with Blueclinical, Ltd. During my internship I was able to contact with various stages of development and coordination of clinical trials, which will be reported in this report.

Curricular internship report in medical writing at Blueclinical, Portugal

The contents of this report are a summary of the activities carried out during the 8-month internship as an Associate Medical Writer at Blueclinical Ltd, Matosinhos, Portugal. Mainly my activities were related to medical writing, particularly writing the clinical research protocols, clinical study reports, writing manuscript and preparing poster presentations. In addition to these activities, I also participated in performance of a clinical trial from beginning to end. During the period of its realization, I was able to familiarize myself with all the steps of the Phase I clinical trial.

Perspetiva atual e futura da nova regulamentação da investigação clínica

A investigação clínica na Europa, e em particular em Portugal, tem vindo a perder competitividade, uma situação preocupante face aos benefícios que a investigação representa para os doentes, instituições, profissionais de saúde e comunidade científica. O quadro regulamentar da investigação clínica em Portugal sofreu alterações significativas em 2014 com a implementação da Lei n.º 21/2014. Adicionalmente, o Regulamento UE n.º 536/2014, publicado no mesmo ano, será implementado a partir de maio de 2016, entrando diretamente em vigor nos países membros. Esta nova regulamentação contribuiu positivamente para o desenvolvimento da investigação clínica em Portugal. No entanto é fundamental colocar em prática todas a medidas promulgadas para que haja um crescimento sustentado do número de estudos clínicos em Portugal.